TCON (TRACON Pharmaceuticals) Growth Rank : 0 (As of Dec. 14, 2024)

View and export this data going back to 2015. Start your Free Trial

What is TRACON Pharmaceuticals Growth Rank?

TRACON Pharmaceuticals has the Growth Rank of 0.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

TRACON Pharmaceuticals Growth Rank Related Terms

Thank you for viewing the detailed overview of TRACON Pharmaceuticals's Growth Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

TRACON Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TRACON Pharmaceuticals Inc (OTCPK:TCON) » Definitions » Growth Rank

Comparable Companies

Traded in Other Exchanges

N/A

Address

4350 La Jolla Village Drive, Suite 800, San Diego, CA, USA, 92122

Website

https://www.traconpharma.com

TRACON Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer and utilizing its cost efficient, contract research organization (CRO) independent product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the United States. The company's drug candidate includes Envafolimab, TRC102, TRC253, and Bispecific Antibodies.

Executives

Opaleye Management Inc.	10 percent owner	ONE BOSTON PLACE, SUITE 2600, BOSTON MA 02108
Charles Theuer	director, officer: President and CEO	C/O TRACON PHARMACEUTICALS, INC., 4350 LA JOLLA VILLAGE DRIVE, SUITE 800, SAN DIEGO CA 92122
Bonne J. Adams	officer: Chief Operating Officer	C/O TRACON PHARMACEUTICALS, INC., 4350 LA JOLLA VILLAGE DRIVE, SUITE 800, SAN DIEGO CA 92122
Scott B. Brown	officer: Chief Accounting Officer (PAO)	C/O TRACON PHARMACEUTICALS, INC., 4350 LA JOLLA VILLAGE DRIVE, SUITE 800, SAN DIEGO CA 92122
William R Larue	director	C/O TRACON PHARMACEUTICALS, INC., 8910 UNIVERSITY CENTER LANE, SUITE 700, SAN DIEGO CA 92122
Carol C. Lam	director	C/O TRACON PHARMACEUTICALS, INC., 4350 LA JOLLA VILLAGE DRIVE, STE 800, SAN DIEGO CA 92122
Saundra L Pelletier	director	C/O EVOFEM BIOSCIENCES, INC., 12400 HIGH BLUFF DRIVE, SUITE 600, SAN DIEGO CA 92130
Lisa Johnson-pratt	director	C/O TRACON PHARMACEUTICALS, INC., 4350 LA JOLLA VILLAGE DRIVE, SUITE 800, SAN DIEGO CA 92122
Ikarian Healthcare Master Fund, L.p.	10 percent owner, other: Member of 10% Group	100 CRESCENT COURT, SUITE 1620, DALLAS TX 75201
Mark C Wiggins	officer: Chief Business Officer	12671 HIGH BLUFF DRIVE SUITE 200, SAN DIEGO CA 92130
Neil Shahrestani	10 percent owner, other: Member of 10% Group	12806 WINDING CREEK DRIVE, FRISCO TX 75035
Ikarian Healthcare Fund Gp, L.p.	10 percent owner, other: Member of 10% Group	100 CRESCENT COURT, SUITE1620, DALLAS TX 75201
Chart Westcott Living Trust	10 percent owner, other: Member of 10% Group	100 CRESCENT COURT, SUITE1620, DALLAS TX 75201
Ikarian Capital, Llc	10 percent owner, other: Member of 10% Group	100 CRESCENT COURT, SUITE 1620, DALLAS TX 75201
Puissance Cross-border Opportunities V Llc	10 percent owner	950 THIRD AVENUE, 25TH FL, NEW YORK NY 10022